Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
Phospho-N-acetylmuramoyl pentapeptide transferase | 2 |
Mechanism Phospho-N-acetylmuramoyl pentapeptide transferase inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism Phospho-N-acetylmuramoyl pentapeptide transferase inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date28 Jul 2023 |
Sponsor / Collaborator [+7] |
Start Date06 May 2021 |
Sponsor / Collaborator |
Start Date01 Apr 2013 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
SQ-641 ( Phospho-N-acetylmuramoyl pentapeptide transferase ) | Crohn Disease More | Preclinical |
SQ-922 ( Phospho-N-acetylmuramoyl pentapeptide transferase ) | Pulmonary Tuberculosis More | Preclinical |
SQ-109 ( MmpL3 ) | Pulmonary Tuberculosis More | Pending |
Sutezolid ( 50S subunit ) | Pulmonary Tuberculosis More | Pending |
Tuberculosis Peptide Vaccine (EpiVax/Sequella/Valneva) | Tuberculosis More | Pending |